PL2912186T3 - Leczenie ukierunkowane na płytki krwi - Google Patents

Leczenie ukierunkowane na płytki krwi

Info

Publication number
PL2912186T3
PL2912186T3 PL13848463T PL13848463T PL2912186T3 PL 2912186 T3 PL2912186 T3 PL 2912186T3 PL 13848463 T PL13848463 T PL 13848463T PL 13848463 T PL13848463 T PL 13848463T PL 2912186 T3 PL2912186 T3 PL 2912186T3
Authority
PL
Poland
Prior art keywords
targeted treatment
platelet
platelet targeted
treatment
targeted
Prior art date
Application number
PL13848463T
Other languages
English (en)
Polish (pl)
Inventor
David A. Wilcox
Sandra L. Haberichter
Original Assignee
Platelet Targeted Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Platelet Targeted Therapeutics Llc filed Critical Platelet Targeted Therapeutics Llc
Publication of PL2912186T3 publication Critical patent/PL2912186T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/7055—Integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL13848463T 2012-10-24 2013-10-24 Leczenie ukierunkowane na płytki krwi PL2912186T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261717951P 2012-10-24 2012-10-24
EP13848463.9A EP2912186B1 (en) 2012-10-24 2013-10-24 Platelet targeted treatment
PCT/US2013/066651 WO2014066663A1 (en) 2012-10-24 2013-10-24 Platelet targeted treatment

Publications (1)

Publication Number Publication Date
PL2912186T3 true PL2912186T3 (pl) 2021-06-14

Family

ID=50545271

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13848463T PL2912186T3 (pl) 2012-10-24 2013-10-24 Leczenie ukierunkowane na płytki krwi

Country Status (12)

Country Link
US (4) US9982034B2 (cg-RX-API-DMAC7.html)
EP (2) EP3859004A1 (cg-RX-API-DMAC7.html)
JP (2) JP2016501515A (cg-RX-API-DMAC7.html)
KR (1) KR101819803B1 (cg-RX-API-DMAC7.html)
BR (1) BR112015009229B1 (cg-RX-API-DMAC7.html)
CA (1) CA2888982C (cg-RX-API-DMAC7.html)
DK (1) DK2912186T3 (cg-RX-API-DMAC7.html)
ES (1) ES2854754T3 (cg-RX-API-DMAC7.html)
IL (1) IL238417B (cg-RX-API-DMAC7.html)
PL (1) PL2912186T3 (cg-RX-API-DMAC7.html)
WO (1) WO2014066663A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201502945B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11319528B2 (en) 2015-07-13 2022-05-03 University Of Utah Research Foundation Methods of making red blood cells and platelets in vitro and uses thereof
US20200291356A1 (en) * 2019-03-13 2020-09-17 Cellphire, Inc. Canine blood platelet preparations
EP3735457A4 (en) 2018-01-05 2021-08-25 Platelet Biogenesis, Inc. COMPOSITIONS AND METHOD OF MANUFACTURING MEGAKARYOCYTE
WO2020006539A1 (en) 2018-06-29 2020-01-02 Platelet Biogenesis, Inc. Compositions for drug delivery and methods of use thereof
EP3861102A4 (en) * 2018-10-05 2022-07-13 University of Utah Research Foundation Methods of making platelets comprising modified receptors and uses thereof
WO2020112963A1 (en) 2018-11-30 2020-06-04 Cellphire, Inc. Platelets as delivery agents
AU2019389141A1 (en) 2018-11-30 2021-06-17 Cellphire, Inc. Platelets loaded with anti-cancer agents
US11529587B2 (en) 2019-05-03 2022-12-20 Cellphire, Inc. Materials and methods for producing blood products
US11701388B2 (en) 2019-08-16 2023-07-18 Cellphire, Inc. Thrombosomes as an antiplatelet agent reversal agent
WO2021158645A1 (en) 2020-02-04 2021-08-12 Cellphire, Inc. Methods of treating congenital hemophilia with anti-fibrinolytic loaded platelets
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
TW202245814A (zh) 2021-02-17 2022-12-01 美商賽菲爾公司 用於治療抗血小板誘導的凝血病之凍乾血小板衍生物組成物

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2452892A (en) 1947-05-07 1948-11-02 Robert A Appleton Igniter for rockets
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
EP1167378B1 (en) 1994-07-15 2011-05-11 University of Iowa Research Foundation Immunomodulatory oligonucleotides
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
DE69719761T2 (de) 1996-06-18 2003-12-18 Alza Corp., Palo Alto Vorrichtung zur verbesserung der transdermalen verabreichung von medikamenten oder der abnahme von körperflüssigkeiten
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
AU722574B2 (en) 1996-12-20 2000-08-10 Alza Corporation Device and method for enhancing transdermal agent flux
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
EP1279401B1 (en) 1997-09-05 2008-01-09 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
CA2312900A1 (en) 1997-12-02 1999-06-10 Powderject Vaccines, Inc. Transdermal delivery of particulate vaccine compositions
EP1048736A1 (en) * 1999-04-27 2000-11-02 Aventis Behring Gesellschaft mit beschränkter Haftung DNA-construct for the tissue specific expression of a blood coagulation factor
CA2450125A1 (en) * 2001-06-15 2002-12-27 Andre C. Schuh Gene therapy for hemophilia a
DK1412493T3 (da) 2001-08-02 2012-01-09 Inst Clayton De La Rech Fremgangsmåder og sammensætninger der angår forbedrede lentiviral-vektor.-produktionsystemer
AU2002347062B2 (en) 2001-10-06 2008-06-26 Merial Ltd CpG formulations and related methods
EP1656156A2 (en) 2003-08-13 2006-05-17 Children's Hospital Medical Center Mobilization of hematopoietic cells
AU2005300688B2 (en) * 2004-11-03 2012-02-02 Almac Diagnostics Limited Transcriptome microarray technology and methods of using the same
KR100981092B1 (ko) * 2008-02-29 2010-09-08 고려대학교 산학협력단 제8 혈액응고 인자와 폰 빌리 블란트 인자 변이체의 재조합발현 벡터 시스템
WO2010075303A1 (en) * 2008-12-23 2010-07-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Splicing factors with a puf protein rna-binding domain and a splicing effector domain and uses of same
US8147820B2 (en) 2009-09-14 2012-04-03 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Attenuated vaccine against fish pathogen Francisella sp
JP5876416B2 (ja) 2009-11-13 2016-03-02 グリフオルス・セラピユーテイクス・インコーポレーテツドＧｒｉｆｏｌｓ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． フォンウィルブランド因子（ｖＷＦ）含有調製品並びにこれに関連する方法、キット及び使用
WO2012119103A2 (en) 2011-03-02 2012-09-07 Proteonomix, Inc. Compositions and methods for mobilization of stem cells

Also Published As

Publication number Publication date
HK1211986A1 (en) 2016-06-03
US20150344541A1 (en) 2015-12-03
JP6975105B2 (ja) 2021-12-01
ZA201502945B (en) 2016-11-30
WO2014066663A1 (en) 2014-05-01
IL238417B (en) 2019-07-31
EP3859004A1 (en) 2021-08-04
KR20150069017A (ko) 2015-06-22
US9982034B2 (en) 2018-05-29
BR112015009229B1 (pt) 2021-07-20
US10294291B2 (en) 2019-05-21
ES2854754T3 (es) 2021-09-22
EP2912186A4 (en) 2016-06-08
JP2018161152A (ja) 2018-10-18
JP2016501515A (ja) 2016-01-21
US20180009874A1 (en) 2018-01-11
US20240270822A1 (en) 2024-08-15
DK2912186T3 (da) 2021-02-22
CA2888982C (en) 2020-07-21
US20190270791A1 (en) 2019-09-05
BR112015009229A2 (pt) 2017-11-14
EP2912186B1 (en) 2021-01-06
EP2912186A1 (en) 2015-09-02
CA2888982A1 (en) 2014-05-01
IL238417A0 (en) 2015-06-30
KR101819803B1 (ko) 2018-01-17

Similar Documents

Publication Publication Date Title
ZA201502945B (en) Platelet targeted treatment
GB201217439D0 (en) Combination therapy
GB2521289B (en) Formation treatment system
GB201207305D0 (en) Therapy
EP2864362A4 (en) ANTICANCER TREATMENT
EP2879707A4 (en) COMBINATION THERAPY
ZA201308117B (en) Avian-based treatment
EP2804853A4 (en) THERAPEUTIC USES
GB201102283D0 (en) Treatment
GB201211135D0 (en) Treatment
GB201208690D0 (en) Treatment
GB201212604D0 (en) New treatment
GB201221118D0 (en) Methods of treatment
GB201216740D0 (en) Methods of treatment
GB201216748D0 (en) Methods of treatment
GB201206326D0 (en) Methods of treatment
GB201206325D0 (en) Methods of treatment
GB201206330D0 (en) Methods of treatment
GB201206324D0 (en) Methods of treatment
GB201211543D0 (en) Combination therapy
GB201214551D0 (en) Anticancer treatment
GB201221326D0 (en) Novel treatments
GB201102277D0 (en) Treatment
GB201102274D0 (en) Treatment
GB201102270D0 (en) Treatment